Synergy Biomedical received FDA 510(k) clearance and commenced full launch of BIOSPHERE® MIS PUTTY, comprising a pre-loaded bone graft cannula and trigger-based delivery system for open, mini-open and percutaneous minimally invasive procedures.
The system is available as a kit (with dispenser and putty-filled cannula) and in individual replacement cannulas to reload the delivery system.
BIOSPHERE bioactive glass-based bone graft putty has been marketed in the U.S. since 2013 and received CE Mark approval in 2017.
Sources: Synergy Biomedical, LLC; ORTHOWORLD Inc.
Synergy Biomedical received FDA 510(k) clearance and commenced full launch of BIOSPHERE® MIS PUTTY, comprising a pre-loaded bone graft cannula and trigger-based delivery system for open, mini-open and percutaneous minimally invasive procedures.
The system is available as a kit (with dispenser and putty-filled cannula) and in individual...
Synergy Biomedical received FDA 510(k) clearance and commenced full launch of BIOSPHERE® MIS PUTTY, comprising a pre-loaded bone graft cannula and trigger-based delivery system for open, mini-open and percutaneous minimally invasive procedures.
The system is available as a kit (with dispenser and putty-filled cannula) and in individual replacement cannulas to reload the delivery system.
BIOSPHERE bioactive glass-based bone graft putty has been marketed in the U.S. since 2013 and received CE Mark approval in 2017.
Sources: Synergy Biomedical, LLC; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.